[
  {
    "ts": null,
    "headline": "Why The Narrative Around West Pharmaceutical Services (WST) Is Shifting On 2026 Outlook And Valuation",
    "summary": "West Pharmaceutical Services just saw its fair value estimate nudged slightly, with the price target essentially steady at about US$345.71 per share, while the discount rate and revenue growth inputs were both adjusted only modestly. These tweaks reflect how recent Street research has folded refreshed EPS assumptions and a more constructive tone on growth drivers into the existing framework, rather than resetting the story around the stock. Stay with this article to see how you can keep on...",
    "url": "https://finnhub.io/api/news?id=42a8ba501a8f44026b9193eb01272e0da59d9639e79ed8e902d0ef045e872283",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767993015,
      "headline": "Why The Narrative Around West Pharmaceutical Services (WST) Is Shifting On 2026 Outlook And Valuation",
      "id": 138052310,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "WST",
      "source": "Yahoo",
      "summary": "West Pharmaceutical Services just saw its fair value estimate nudged slightly, with the price target essentially steady at about US$345.71 per share, while the discount rate and revenue growth inputs were both adjusted only modestly. These tweaks reflect how recent Street research has folded refreshed EPS assumptions and a more constructive tone on growth drivers into the existing framework, rather than resetting the story around the stock. Stay with this article to see how you can keep on...",
      "url": "https://finnhub.io/api/news?id=42a8ba501a8f44026b9193eb01272e0da59d9639e79ed8e902d0ef045e872283"
    }
  }
]